title: Safety of prohemostatic interventions.
abstract: Pharmacological prohemostatic agents may be useful adjunctive treatment options in patients with severe blood loss. The efficacy of these interventions has been established in a variety of clinical situations. However, the procoagulant effect of these interventions may tip the balance toward a higher risk of thrombotic complications. Several studies have shown that some prohemostatic interventions may indeed increase the risk of arterial and venous thromboembolism, although these complications are relatively rare. When considering the use of adjunctive prohemostatic agents to prevent or treat excessive blood loss, the risk of thrombotic complications should be taken into account.
authors.affiliation: Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.m.levi@amc.uva.nl
authors.forename: Marcel
authors.initials: M
authors.lastname: Levi
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions; D006470:Hemorrhage / Q000188:drug therapy; D006490:Hemostatics / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D006490:Hemostatics